Jeffrey M Jacobson1, Charles W Flexner. 1. aDepartments of Medicine and Neuroscience, Center for Translational AIDS Research, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania bDivisions of Clinical Pharmacology and Infectious Diseases, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Poor adherence to oral antiretroviral treatment in a subpopulation of persons with HIV-1 infection interferes with the potential success of the drug regimens in treating the infection. Here, we review long-acting antiretroviral strategies currently in clinical development that could prove useful for the treatment of HIV-1 infection in individuals not succeeding with short-acting oral regimens. RECENT FINDINGS: Pharmaceutical nanotechnology has succeeded in creating two novel long-acting injectable antiretroviral compounds, carbotegravir and rilpivirine, which have completed early clinical trials demonstrating the safety, tolerability and prolonged antiretroviral activity. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA; MK8591) is a novel nucleoside reverse transcriptase inhibitor in early clinical development as a long-acting orally administered drug and in a long-acting polymer implant. Broadly neutralizing and cell-entry inhibitor monoclonal antibodies have demonstrated potent antiviral activity in early human trials; however, there is substantial baseline resistance. In addition, monotherapy leads to rapid resistance in those with baseline susceptibility. SUMMARY: Long-acting antiretroviral chemical compounds and monoclonal antibodies have demonstrated potent anti-HIV activity in the early-stage clinical investigations, and are actively being studied in advanced clinical trials for treatment and prevention. Strategies to manage toxicities and waning drug levels of chemical compounds, as well as primary and secondary resistance to current monoclonal antibodies are important considerations.
PURPOSE OF REVIEW: Poor adherence to oral antiretroviral treatment in a subpopulation of persons with HIV-1 infection interferes with the potential success of the drug regimens in treating the infection. Here, we review long-acting antiretroviral strategies currently in clinical development that could prove useful for the treatment of HIV-1 infection in individuals not succeeding with short-acting oral regimens. RECENT FINDINGS: Pharmaceutical nanotechnology has succeeded in creating two novel long-acting injectable antiretroviral compounds, carbotegravir and rilpivirine, which have completed early clinical trials demonstrating the safety, tolerability and prolonged antiretroviral activity. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA; MK8591) is a novel nucleoside reverse transcriptase inhibitor in early clinical development as a long-acting orally administered drug and in a long-acting polymer implant. Broadly neutralizing and cell-entry inhibitor monoclonal antibodies have demonstrated potent antiviral activity in early human trials; however, there is substantial baseline resistance. In addition, monotherapy leads to rapid resistance in those with baseline susceptibility. SUMMARY: Long-acting antiretroviral chemical compounds and monoclonal antibodies have demonstrated potent anti-HIV activity in the early-stage clinical investigations, and are actively being studied in advanced clinical trials for treatment and prevention. Strategies to manage toxicities and waning drug levels of chemical compounds, as well as primary and secondary resistance to current monoclonal antibodies are important considerations.
Authors: Tae-Wook Chun; Danielle Murray; Jesse S Justement; Jana Blazkova; Claire W Hallahan; Olivia Fankuchen; Kathleen Gittens; Erika Benko; Colin Kovacs; Susan Moir; Anthony S Fauci Journal: Proc Natl Acad Sci U S A Date: 2014-08-25 Impact factor: 11.205
Authors: Marina Caskey; Florian Klein; Julio C C Lorenzi; Michael S Seaman; Anthony P West; Noreen Buckley; Gisela Kremer; Lilian Nogueira; Malte Braunschweig; Johannes F Scheid; Joshua A Horwitz; Irina Shimeliovich; Sivan Ben-Avraham; Maggi Witmer-Pack; Martin Platten; Clara Lehmann; Leah A Burke; Thomas Hawthorne; Robert J Gorelick; Bruce D Walker; Tibor Keler; Roy M Gulick; Gerd Fätkenheuer; Sarah J Schlesinger; Michel C Nussenzweig Journal: Nature Date: 2015-04-08 Impact factor: 49.962
Authors: Kyle J Nakamura; Chiara Cerini; Edwin R Sobrera; Laura Heath; Moses Sinkala; Chipepo Kankasa; Donald M Thea; James I Mullins; Louise Kuhn; Grace M Aldrovandi Journal: AIDS Date: 2013-01-28 Impact factor: 4.177
Authors: Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola Journal: Science Date: 2010-07-08 Impact factor: 47.728
Authors: Jose D Murga; Michael Franti; Daniel C Pevear; Paul J Maddon; William C Olson Journal: Antimicrob Agents Chemother Date: 2006-10 Impact factor: 5.191
Authors: Guido Ferrari; Barton F Haynes; Scott Koenig; Jeffrey L Nordstrom; David M Margolis; Georgia D Tomaras Journal: Nat Rev Drug Discov Date: 2016-10-07 Impact factor: 84.694
Authors: Amy W Chung; Max Crispin; Laura Pritchard; Hannah Robinson; Miroslaw K Gorny; Xiaojie Yu; Chris Bailey-Kellogg; Margaret E Ackerman; Chris Scanlan; Susan Zolla-Pazner; Galit Alter Journal: AIDS Date: 2014-11-13 Impact factor: 4.177
Authors: Jianmeng Chen; Charles Flexner; Rosa G Liberman; Paul L Skipper; Nicolette A Louissaint; Steven R Tannenbaum; Craig W Hendrix; Edward J Fuchs Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: Panita Maturavongsadit; Roopali Shrivastava; Craig Sykes; Mackenzie L Cottrell; Stephanie A Montgomery; Angela D M Kashuba; S Rahima Benhabbour Journal: Int J Pharm Date: 2021-07-01 Impact factor: 6.510